Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ciro Celsa

Showing results (91-100 of 115) with videos related to

Pageof 12
Sort By:
Annals of Surgery|January 26, 2022
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted ComparisonSimone Famularo, Matteo Donadon, Federica Cipriani, et al.
Oncology Research|April 3, 2026
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and DiabetesAndrea Dalbeni, Marco Vicardi, Leonardo A Natola, et al.
Blood Advances|February 9, 2021
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19Erica Villa, Rosina Critelli, Simone Lasagni, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 4, 2026
Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF)Stefano Gitto, Filippo Gabrielli, Giovanni Addolorato, et al.
Cancers|March 6, 2021
Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma PatientsFilippo Pelizzaro, Alessandro Vitale, Anna Sartori, et al.
JHEP Reports : Innovation in Hepatology|December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN studyPasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 12, 2022
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinibMargherita Rimini, Wonseok Kang, Valentina Burgio, et al.
Liver Cancer|April 22, 2026
Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular CarcinomaEdoardo G Giannini, Andrea Pasta, Giulia Pieri, et al.
Cancer Management and Research|January 7, 2022
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in ItalyValentina Burgio, Massimo Iavarone, Giovanni Giuseppe Di Costanzo, et al.
Scientific Reports|August 30, 2024
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus BevacizumabMargherita Rimini, Margarida Montes, Elisabeth Amadeo, et al.
Pageof 12

Showing results (91-100 of 115) with videos related to

Sort By:
Pageof 12
Annals of Surgery|January 26, 2022
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted ComparisonSimone Famularo, Matteo Donadon, Federica Cipriani, et al.
Oncology Research|April 3, 2026
The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and DiabetesAndrea Dalbeni, Marco Vicardi, Leonardo A Natola, et al.
Blood Advances|February 9, 2021
Dynamic angiopoietin-2 assessment predicts survival and chronic course in hospitalized patients with COVID-19Erica Villa, Rosina Critelli, Simone Lasagni, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 4, 2026
Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF)Stefano Gitto, Filippo Gabrielli, Giovanni Addolorato, et al.
Cancers|March 6, 2021
Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma PatientsFilippo Pelizzaro, Alessandro Vitale, Anna Sartori, et al.
JHEP Reports : Innovation in Hepatology|December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN studyPasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|August 12, 2022
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinibMargherita Rimini, Wonseok Kang, Valentina Burgio, et al.
Liver Cancer|April 22, 2026
Comparative Efficacy of Initial Treatment Strategies in Patients with Transarterial Chemoembolisation-Unsuitable Hepatocellular CarcinomaEdoardo G Giannini, Andrea Pasta, Giulia Pieri, et al.
Cancer Management and Research|January 7, 2022
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in ItalyValentina Burgio, Massimo Iavarone, Giovanni Giuseppe Di Costanzo, et al.
Scientific Reports|August 30, 2024
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus BevacizumabMargherita Rimini, Margarida Montes, Elisabeth Amadeo, et al.
Pageof 12